At a recent cancer research meeting, several important updates were shared about new treatments and trends in the pharmaceutical industry. Here’s what you need to know in simple terms:
1. **Merck & Co. Shares Early Results for a New Lung Cancer Drug**
Merck & Co. presented the first clinical data for a new drug designed to treat non-small cell lung cancer (NSCLC). This drug, called a bispecific antibody, works by targeting two different proteins: PD-1 and VEGF. In an early trial with 11 patients who had not been treated before and had a specific type of lung cancer (PD-L1-positive), the drug showed promising results. About 55% of patients responded to the treatment when given at a dose of 20 mg/kg every three weeks. While these results are still early and not yet confirmed, they suggest the drug is as effective as similar treatments and may have fewer side effects.
2. **Chinese Biotech Company Zai Lab Aims to Expand Beyond China**
Zai Lab, a biotechnology company based in China, is working to become a global leader in developing new drugs. One of their most promising treatments is an antibody-drug conjugate called zocilurtatug pelitecan, which targets a protein called DLL3 found in some cancers. However, Zai Lab’s president and chief operating officer, Josh Smiley, explained that Chinese biotech companies still rely heavily on partnerships with larger global pharmaceutical companies for funding. This is because investments in China often don’t provide enough financial returns to support long-term growth.
3. **New Obesity Drug Company Kailera Therapeutics Raises Record $625 Million**
Kailera Therapeutics, a company focused on developing obesity treatments, made a strong entrance into the public market with a record-breaking $625 million initial public offering (IPO). The company’s treatments are based on a portfolio of drugs called GLP-1 agonists, which were licensed from Hengrui Pharma, a Chinese pharmaceutical company. Kailera CEO Ron Renaud shared that the company was confident in its success even before the IPO, thanks to strong interest from investors. The company raised $400 million in a private funding round just earlier this year, making its path to the public market very quick.
4. **Former FDA Official Highlights Challenges and Concerns About Drug Approvals**
Richard Pazdur, M.D., a former top official at the U.S. Food and Drug Administration (FDA), spoke about the challenges facing the agency, including political influences and a general sense of anxiety among regulators. He specifically mentioned the need for greater collaboration with regulatory authorities in China and other Asian countries. The FDA currently has a program called Project Orbis, which allows for simultaneous reviews of drug applications with other countries, but Pazdur believes this collaboration should be expanded to include more regions.
5. **New Neurology Startup Tortugas Neuroscience Raises $106 Million**
A new company called Tortugas Neuroscience, led by experts from Sage Therapeutics, has raised $106 million to develop four new treatments for neurological conditions such as schizophrenia. The company’s pipeline includes drugs licensed from Chinese and Japanese pharmaceutical companies, including treatments that target the GABA receptor and enzymes like GAT-1 and PDE9.
6. **Samsung Biologics Reports Strong Revenue Growth Amid Labor Concerns**
Samsung Biologics, a major player in the biopharmaceutical manufacturing industry, reported significant revenue growth. However, the company is facing challenges as its labor union prepares for a potential strike, which could impact operations.
7. **Biogen Partners with Chinese Company to Develop a New Immunotherapy**
Biogen has signed a deal worth up to $850 million with TJ Biopharma to develop and commercialize an immune-targeting antibody in China. This agreement focuses on a late-stage treatment for immune-related conditions.